Global Mutual Presses Ahead With First Phase of Refurbishment at Riverlabs, Its 440,000 Sq Ft Life Science Campus in Ware
Intelligent upgrade of existing, purpose-built laboratory spaces will be available for occupation from Q3, 2025
Intelligent upgrade of existing, purpose-built laboratory spaces will be available for occupation from Q3, 2025
On 30 January, a high-level delegation from the Department for Science, Innovation and Technology (DSIT) visited Norwich Research Park, to see the cutting edge research and innovation in Engineering Biology that is being conducted on campus.
To mark the 10th anniversary of the United Nation’s ‘International Day of Women and Girls in Science’ on February 11th, 2025 - AMSBIO has interviewed Dr Zoe Hewitt, an expert in cell and gene therapy manufacturing, and co-founder of Regen CTC*.
We are seeking a talented Data Scientist to work on an exciting project for the development of Digital Twins for rare disease. You will work within a multidisciplinary project team, across the Open Targets, BioModels and Petsalaki research groups at the EMBL European Bioinformatics Institute (EMBL-EBI). This project is funded through the Chan Zuckerberg Initiative with a strong emphasis on making datasets and models open source where possible.
Learn to Discover (L2D) is a cutting edge online training course in Python programming, data science and machine learning, tailored for health, disease and bioscience. L2D is accredited for CPD purposes by the Royal College of Physicians and the Royal Society of Biology and was developed at University College London.
To register your interest, please contact: admin@learntodiscover.ai
Learn to Discover (L2D) is a cutting edge online training course in Python programming, data science and machine learning, tailored for health, disease and bioscience. L2D is accredited for CPD purposes by the Royal College of Physicians and the Royal Society of Biology and was developed at University College London.
To register your interest, please contact admin@learntodiscover.ai
Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer Group and Novo Nordisk’s 2025 Golden Ticket Programme.
The 2025 Golden Ticket Programme was open to early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic diseases, rare blood and rare endocrine disorders, with robust research plans and potential for successful research development.
London, February 11, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (“Bausch Health”) and is pleased to announce the placement of Jonathan Sadeh M.D., M.Sc.,as Executive Vice President, Chief Medical Officer and Head of R&D.
Job type: 1.5-year fixed term contract
Location: Oxford
Company: OMass Therapeutics
Right to work: You must have the right to work in the UK
Application deadline: 28th February 2025
Application submission: CV and cover letter via our website www.omass.com/working-here/